Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
NNZ-2591 in Prader-Willi syndrome
Investor Information
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Home
>
News & Reports
>
ASX Announcements
Font Smaller
Font larger
Print Page
ASX Announcements
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
28-Apr-2022
Virtual AGM online guide
28-Apr-2022
Notice of Annual General Meeting/Proxy Form
27-Apr-2022
Change in substantial holding
27-Apr-2022
Appendix 4G
27-Apr-2022
Annual Report to shareholders
25-Mar-2022
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
23-Mar-2022
FDA approval for Phelan-McDermid IND and Phase 2 trial
11-Mar-2022
Ethics approval for Angelman Phase 2 trial in Australia
4-Mar-2022
S&P DJI Announces March 2022 Quarterly Rebalance
25-Feb-2022
Investor presentation 25 Feb 2022
25-Feb-2022
FDA approval for Angelman IND and Phase 2 trial
24-Feb-2022
2021 Results - a transformational year for Neuren
24-Feb-2022
Preliminary Final Report and 2021 Full Year Accounts
3-Feb-2022
Notification regarding unquoted securities - NEU
1-Feb-2022
Neuren appoints Vice President, Corporate Development
31-Jan-2022
Q4 2021 quarterly activity and cash flow report
10-Dec-2021
Becoming a substantial holder
7-Dec-2021
Positive topline results from Phase 3 trial in Rett syndrome
10-Nov-2021
Neuren presenting at Bell Potter Healthcare Conference
28-Oct-2021
Q3 2021 quarterly activity and cash flow report
21-Oct-2021
Neuren receives feedback on IND for Phelan-McDermid syndrome
20-Oct-2021
Change of Director's Interest Notice - D Angus
11-Oct-2021
US patent to 2034 granted for Neuren's NNZ-2591 in autism
8-Oct-2021
Change of Director's Interest Notice - J Harry
8-Oct-2021
Change of Director's Interest Notice - J Pilcher
8-Oct-2021
Change of Director's Interest Notice - P Davies
8-Oct-2021
Application for quotation of securities - NEU
6-Oct-2021
Update - Proposed issue of securities - NEU
6-Oct-2021
$3.3 million raised from oversubscribed SPP
1-Oct-2021
Feedback on Angelman IND and submission of Pitt Hopkins IND
21-Sep-2021
IND application submitted for NNZ-2591 in Phelan-McDermid
17-Sep-2021
Share Purchase Plan Offer Booklet
16-Sep-2021
Section 708A Notice
16-Sep-2021
New patent issued to 2032 for Neuren's trofinetide in Brazil
16-Sep-2021
Application for quotation of securities - NEU
13-Sep-2021
Investor Presentation, 13 September 2021
13-Sep-2021
Proposed issue of securities - NEU
13-Sep-2021
Placement to accelerate NNZ-2591 across 4 indications
10-Sep-2021
Notification of investor presentation, 9.00 AEST 13 Sept 21
9-Sep-2021
Trading Halt
3-Sep-2021
FDA grants Orphan Drug designation for Prader-Willi syndrome
1-Sep-2021
Angelman IND and Ethics applications submitted for NNZ-2591
1-Sep-2021
Trofinetide Rett syndrome clinical trial in girls aged 2-5
30-Aug-2021
R&D Tax Incentive Advance Overseas Finding Approval
25-Aug-2021
Half-year shareholder update
25-Aug-2021
Half Yearly Report and Accounts
17-Aug-2021
Notification of investor webinar
5-Aug-2021
Phase 3 enrolment successfully completed, results in Q4 2021
30-Jul-2021
Q2 2021 quarterly activity and cash flow report
28-Jun-2021
Change of Director's Interest Notice
22-Jun-2021
Results of Meeting
22-Jun-2021
AGM Chairman's Address and CEO Presentation
16-Jun-2021
Change of Director's Interest Notice
15-Jun-2021
Investor presentation, 15 June 2021
15-Jun-2021
Initial Director's Interest Notice
15-Jun-2021
Neuren CEO Jon Pilcher appointed to board of directors
10-Jun-2021
Neuren to present at MST Access investor conference
10-Jun-2021
Update - Annual General Meeting 2021
1-Jun-2021
Positive FDA meetings enable INDs for three Phase 2 trials
21-May-2021
Virtual AGM online guide
21-May-2021
Notice of Annual General Meeting/Proxy Form
29-Apr-2021
New patent issued to 2032 for Neuren's trofinetide in Canada
27-Apr-2021
Appendix 4G
27-Apr-2021
Annual Report 2020
22-Apr-2021
Quarterly report and cash flow statement for Q1 2021
23-Mar-2021
Investor presentation, 23 March 2021
12-Mar-2021
S&P DJI Announces March 2021 Quarterly Rebalance
10-Mar-2021
Neuren successfully completes manufacturing for Phase 2
24-Feb-2021
Neuren corporate presentation, 24 February 2021
24-Feb-2021
Neuren approaching transforming milestones in 2021
24-Feb-2021
Preliminary Final Report and 2020 full year accounts
18-Feb-2021
Change of Director's Interest Notice
17-Feb-2021
Notification of investor briefing webinar
16-Feb-2021
Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
15-Feb-2021
Successful Phase 1 trial for Neuren's NNZ-2591
29-Jan-2021
Quarterly report and cash flow statement for Q4 2020
11-Jan-2021
European Commission grants 3 NNZ-2591 Orphan designations
7-Dec-2020
Notification of investor briefing webinar
7-Dec-2020
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591
19-Nov-2020
Approval received for final stage of NNZ-2591 clinical trial
29-Oct-2020
Quarterly report and cash flow statement for Q3 2020
29-Sep-2020
Neuren requests Orphan designations for NNZ-2591 in Europe
22-Sep-2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
26-Aug-2020
Half-year Shareholder Update
26-Aug-2020
Half Yearly Report and Accounts
18-Aug-2020
Corporate presentation, 18 August 2020
11-Aug-2020
Change of Director's Interest Notice
7-Aug-2020
Appendix 2A
7-Aug-2020
Change of Director's Interest Notice
5-Aug-2020
Completion of Share Purchase Plan
30-Jul-2020
Appointment of CFO & Company Secretary
27-Jul-2020
Q2 2020 Activity Report and Cash Flow Report
14-Jul-2020
Final share buy-back notice - Appendix 3F
14-Jul-2020
Announcement of buy-back - Appendix 3C
14-Jul-2020
Scientific publications and presentations for trofinetide and NNZ-2591
13-Jul-2020
Appendix 3G
9-Jul-2020
Share Purchase Plan Offer Booklet
6-Jul-2020
Section 708A notice
6-Jul-2020
Appendix 2A
1-Jul-2020
Electing to receive SPP documents by e-mail
29-Jun-2020
Results of Meeting
29-Jun-2020
AGM Chairman's Address and CEO Presentation
29-Jun-2020
Proposed issue of Securities - NEU
29-Jun-2020
Neuren successfully completes $20m capital raising
25-Jun-2020
Trading Halt
16-Jun-2020
Temporary enrolment pause ended in Phase 3 trial in the US
2-Jun-2020
Change of Director's Interest Notice
1-Jun-2020
Change of Director's Interest Notice
29-May-2020
Final Director's Interest Notice
28-May-2020
Virtual AGM online guide
28-May-2020
Notice of Annual General Meeting/Proxy Form
27-May-2020
Neuren announces changes to leadership team
7-May-2020
Neuren commences first clinical trial for NNZ-2591
29-Apr-2020
Appendix 4G
29-Apr-2020
Annual Report 2019
17-Apr-2020
Appendix 4C - quarterly
17-Apr-2020
Q1 2020 Activity Report
6-Apr-2020
Corporate presentation, 6 April 2020
2-Apr-2020
First patent in Israel granted for trofinetide
26-Mar-2020
Change of Director's Interest Notice
26-Mar-2020
New international institutional shareholder acquires 14% of Neuren
24-Mar-2020
Change of Director's Interest Notice
24-Mar-2020
Temporary pause in new enrolments for LAVENDER trial in US
20-Mar-2020
Trading Halt
17-Mar-2020
Neuren to capture substantially greater value after Phase 3
10-Mar-2020
Additional information
6-Mar-2020
Compelling results for NNZ-2591 dose ranging study in Phelan-McDermid syndrome model
4-Mar-2020
Commentary on potential benefit to Neuren of RPD designation
4-Mar-2020
Rare Pediatric Disease designation received from FDA
26-Feb-2020
5 Orphan Drug programs and Rett in Phase 3 funded by partner
26-Feb-2020
Appendix 4E and 2019 full year accounts
19-Feb-2020
Update on trofinetide Phase 3 trial in Rett syndrome
28-Jan-2020
Appendix 4C - quarterly
12-Dec-2019
2019 year-end update and 2020 outlook
3-Dec-2019
Patent to 2034 granted in Europe for Neuren's NNZ-2591
31-Oct-2019
Phase 3 trial of trofinetide in Rett syndrome commences
18-Oct-2019
Neuren Corporate Presentation, October 2019
17-Oct-2019
Appendix 4C - quarterly
16-Oct-2019
FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes
16-Oct-2019
Pause in Trading
11-Oct-2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
20-Sep-2019
Neuren approaching key milestones in Q4 2019
28-Aug-2019
Neuren advances pipeline for neurodevelopmental disorders
28-Aug-2019
Half Yearly Report and Accounts
16-Aug-2019
New patent granted for Neuren's NNZ-2591 in Japan
31-Jul-2019
Appendix 4C - quarterly
29-Jul-2019
Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
16-Jul-2019
Neuren receives final payment from Lanstead Capital
28-May-2019
Results of Meeting
28-May-2019
Chairman's Address at 2019 Annual Meeting of Shareholders
17-May-2019
Validation for NNZ-2591 neurodevelopmental disorder pipeline
17-May-2019
NNZ-2591 positive effects in Pitt Hopkins syndrome model
17-May-2019
NNZ-2591 positive effects in Angelman syndrome model
30-Apr-2019
Appendix 4C - quarterly
29-Apr-2019
Notice of Annual General Meeting/Proxy Form
26-Apr-2019
Appendix 4G
26-Apr-2019
Annual Report to shareholders
26-Apr-2019
Update on development plan for NNZ-2591
28-Mar-2019
Neuren's Rett syndrome Phase 2 trial published in Neurology
27-Feb-2019
Fundamentals strong as Neuren advances neuroscience pipeline
27-Feb-2019
Preliminary Final Report and statutory accounts
18-Feb-2019
NNZ-2591 positive effects in Phelan-McDermid syndrome model
4-Feb-2019
Plans for Phase 3 trial in Rett syndrome
1-Feb-2019
Neuren retains ex-North America, appoints investment bank
31-Jan-2019
Appendix 4C - quarterly
3-Jan-2019
Final Director's Interest Notice
31-Dec-2018
Ceasing to be a substantial holder
18-Dec-2018
2018 Year-end Business Update
17-Dec-2018
Larry Glass to retire as a director and continue as CSO
2-Nov-2018
Presentation at AusBiotech Invest and Partnering 2018
31-Oct-2018
Appendix 4C - quarterly
26-Oct-2018
Trofinetide ex-North America exclusive negotiation period
17-Oct-2018
Neuren and ACADIA hold Rett syndrome SAB meeting
1-Oct-2018
Change of Director's Interest Notice
21-Sep-2018
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
6-Sep-2018
Investor presentation, 6 September 2018
31-Aug-2018
Half Yearly Report and Accounts
29-Aug-2018
Neuren and Lanstead agree to pause settlements for 120 days
22-Aug-2018
Appointment of auditor
22-Aug-2018
Neuren receives initial payment of US$10 million from ACADIA
16-Aug-2018
Change of Director's Interest Notice
15-Aug-2018
Change of Director's Interest Notice
7-Aug-2018
Investor update
7-Aug-2018
Neuren and ACADIA announce agreement for North America
31-Jul-2018
Appendix 4C - quarterly
9-Jul-2018
Initial Director's Interest Notice
5-Jul-2018
Initial Director's Interest Notice
5-Jul-2018
Initial Director's Interest Notice
4-Jul-2018
Neuren announces new appointments to the board of directors
18-Jun-2018
Results of Meeting
18-Jun-2018
Chairman's Address at 2018 Annual Shareholders' Meeting
30-May-2018
Change of Director's Interest Notice
30-May-2018
Final share buy-back notice - Appendix 3F
30-May-2018
Announcement of buy-back - Appendix 3C
23-May-2018
Notice under section 708A(5)(e) of the Corporations Act
23-May-2018
Appendix 3B
21-May-2018
Neuren announces investment and exclusive negotiation period
14-May-2018
Notice of Annual General Meeting/Proxy Form
8-May-2018
Appendix 4G
8-May-2018
Annual Report to shareholders
30-Apr-2018
Appendix 4C - quarterly
30-Apr-2018
First patent in Japan granted for Neuren's trofinetide
29-Mar-2018
Full Year Statutory Accounts
29-Mar-2018
Disclosure under Listing Rule 4.3D
9-Mar-2018
S&P DJ Indices Announces March Quarterly Rebalance
28-Feb-2018
Preliminary Final Report
30-Jan-2018
Appendix 4C - quarterly
29-Dec-2017
Final Director's Interest Notice
29-Dec-2017
Non-executive director retirement
27-Dec-2017
Change in substantial holding
5-Dec-2017
Neuren announces new US patent to be granted for NNZ-2591
16-Nov-2017
Consolidation/Split - NEU
16-Nov-2017
Notification under Listing Rule 7.20 of share reorganisation
26-Oct-2017
Appendix 4C - quarterly
13-Oct-2017
Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
6-Oct-2017
Investor presentation, 6 October 2017
5-Oct-2017
Presentations and publication for Rett syndrome trials
30-Aug-2017
Change of Director's Interest Notice
30-Aug-2017
Change of Director's Interest Notice
30-Aug-2017
Change of Director's Interest Notice
29-Aug-2017
Notice under section 708A(5)(e) of the Corporations Act
29-Aug-2017
Appendix 3B
29-Aug-2017
Results of Meeting
24-Aug-2017
Neuren reports 2017 half-year results
24-Aug-2017
Half Yearly Report and Accounts
14-Aug-2017
Notice of special meeting of shareholders
27-Jul-2017
Appendix 4C - quarterly
21-Jul-2017
Becoming a substantial holder
20-Jul-2017
Neuren granted Type B Meeting with FDA for Rett syndrome
19-Jul-2017
Notice under section 708A(5)(e) of the Corporations Act
19-Jul-2017
Appendix 3B
13-Jul-2017
Notice under section 708A(5)(e) of the Corporations Act
13-Jul-2017
Appendix 3B
29-Jun-2017
Results of Meeting
29-Jun-2017
2017 AGM Chairman's Address
29-Jun-2017
Neuren secures funding for key activities for Rett syndrome
28-Jun-2017
Response to ASX Price Query
27-Jun-2017
Trading Halt
2-Jun-2017
Investor presentation, 2 June 2017
31-May-2017
Neuren announces grant of two new patents to 2032
29-May-2017
Notice of Annual General Meeting/Proxy Form
8-May-2017
Response to Appendix 4C Query
28-Apr-2017
Appendix 4C - quarterly
28-Apr-2017
Appendix 4G
28-Apr-2017
Annual Report to shareholders
4-Apr-2017
Neuren receives $1 million R&D Tax Incentive
3-Apr-2017
Investor presentation, 3 April 2017
30-Mar-2017
Full Year Statutory Accounts
22-Mar-2017
Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
17-Mar-2017
Trading Halt
10-Mar-2017
S&P DJ Indices Announces March Quarterly Rebalance
23-Feb-2017
Preliminary Final Report
2-Feb-2017
Investor presentation, 2 February 2017
31-Jan-2017
Appendix 4C - quarterly
30-Jan-2017
Neuren completes Phase 2 trial in pediatric Rett syndrome
6-Dec-2016
Results of Meeting
25-Nov-2016
Investor presentation, 25 November 2016
14-Nov-2016
Notice of special meeting of shareholders
14-Nov-2016
Neuren completes enrolment in Rett syndrome Phase 2 trial
31-Oct-2016
Appendix 4C - quarterly
28-Oct-2016
Neuren receives $0.9m from exercise of last expiring options
28-Oct-2016
Appendix 3B
9-Sep-2016
Change of Melbourne Registry Address Notification
31-Aug-2016
Change of Director's Interest Notice
31-Aug-2016
Appendix 3B
30-Aug-2016
Half Yearly Report and Accounts
25-Aug-2016
Neuren expands Phase 2 Rett syndrome pediatric trial
26-Jul-2016
Appendix 4C - quarterly
24-Jun-2016
Neuren presents at Rettsyndrome.org 2016 Research Symposium
22-Jun-2016
Grant of new patent for Autism Spectrum Disorders
31-May-2016
Results of Meeting
31-May-2016
Chairman's Address to Shareholders
16-May-2016
Change of Director's Interest Notice
13-May-2016
Presentation at 6th Annual TBI Conference, Washington DC
2-May-2016
Notice of Annual General Meeting/Proxy Form
29-Apr-2016
Appendix 4C - quarterly
26-Apr-2016
Neuren Shareholder Update
26-Apr-2016
Results of Phase 2 trial in moderate to severe TBI
22-Apr-2016
Trading Halt
18-Apr-2016
Appendix 4G
18-Apr-2016
Annual Report to shareholders
7-Apr-2016
First subject commences Neuren's Rett syndrome Phase 2 trial
25-Feb-2016
Neuren reports 2015 full-year financial results
25-Feb-2016
Appendix 4E and Financial Report 31 December 2015
29-Jan-2016
Appendix 4C - quarterly
11-Jan-2016
Neuren Investor Presentation, 11 January 2016
4-Jan-2016
Neuren Shareholder Update, January 2016
30-Dec-2015
Appendix 3B
7-Dec-2015
Trofinetide successful in Phase 2 trial in Fragile X
3-Dec-2015
Trading Halt
30-Nov-2015
Grant of composition patent in Europe for Neuren's NNZ-2591
17-Nov-2015
Corporations Act Notice
17-Nov-2015
Appendix 3B
9-Nov-2015
Shareholders provide further support for Rett syndrome
29-Oct-2015
Neuren completes enrolment in INTREPID clinical trial
21-Oct-2015
Appendix 4C - quarterly
13-Oct-2015
IRSF confirms financial support for Neuren's clinical trials
12-Oct-2015
New US patent covering use of trofinetide for Rett syndrome
29-Sep-2015
Neuren provides update on Fragile X and INTREPID trials
25-Aug-2015
Half Yearly Report and Accounts 30 June 2015
14-Aug-2015
trofinetide confirmed as INN for Neuren's NNZ-2566
13-Aug-2015
Neuren confirms orphan drug designations in Europe
31-Jul-2015
Investor presentation, 31 July 2015
30-Jul-2015
Appendix 4C - quarterly
29-Jul-2015
Neuren reports progress in orphan drug programs
1-Jun-2015
Appendix 3B
7-May-2015
Appendix 3B
28-Apr-2015
Results of Meeting
28-Apr-2015
Chairman's Address to Shareholders
22-Apr-2015
Appendix 3B
21-Apr-2015
Appendix 4C - quarterly
26-Mar-2015
Appendix 3B
25-Mar-2015
Notice of Annual General Meeting/Proxy Form
25-Mar-2015
Annual Report to shareholders
2-Mar-2015
Neuren receives response to request for Breakthrough Therapy
25-Feb-2015
Neuren reports 2014 full-year financial results
25-Feb-2015
Preliminary Final Report and 2014 full year accounts
16-Feb-2015
FDA grants Neuren Orphan Drug designation for Rett syndrome
6-Feb-2015
Appendix 3B
5-Feb-2015
Change of Director's Interest Notice
29-Jan-2015
Updated Share Trading Policy
28-Jan-2015
Neuren announces trofinetide as proposed INN for NNZ-2566
27-Jan-2015
Appendix 3B
22-Jan-2015
Appendix 4C - quarterly
8-Jan-2015
Investor Presentation, 8 January 2015
5-Jan-2015
Response to ASX Price Query
30-Dec-2014
Neuren submits Orphan Drug/Breakthrough Therapy applications
23-Dec-2014
Appendix 3B
3-Dec-2014
Appendix 3B
27-Nov-2014
Investor presentation, 27 November 2014
20-Nov-2014
Appendix 3B
12-Nov-2014
Neuren successful in Rett syndrome Phase 2 trial
10-Nov-2014
Trading Halt
28-Oct-2014
Appendix 3B
17-Oct-2014
Appendix 4C - quarterly
9-Oct-2014
Change of Director's Interest Notice
9-Oct-2014
Appendix 3B
24-Sep-2014
Appendix 3B
24-Sep-2014
Issue of long term incentives
24-Sep-2014
Neuren to release Rett Syndrome trial results in November
8-Sep-2014
Enrolment commences in Neuren's Concussion Phase 2 trial
4-Sep-2014
Investor presentation, 4 September 2014
29-Aug-2014
Appendix 3B
28-Aug-2014
Neuren reports 2014 half-year financial results
27-Aug-2014
Half Yearly Report and Accounts
15-Aug-2014
Appendix 3B
12-Aug-2014
Neuren advances NNZ-2591 towards IND application
22-Jul-2014
Appendix 3B
18-Jul-2014
Appendix 4C - quarterly
17-Jul-2014
US$3m increase to US Army grant and INTREPID outlook update
10-Jul-2014
Neuren receives ethics approval to start Concussion trial
26-Jun-2014
Neuren completes enrolment in Phase 2 trial in Rett Syndrome
25-Jun-2014
Appendix 3B
23-Jun-2014
Neuren appoints CMC expert to leadership team
4-Jun-2014
Neuren receives new US patent for NNZ-2591
3-Jun-2014
Appendix 3B
3-Jun-2014
Appendix 3B
30-May-2014
Appendix 3B
21-May-2014
Neuren presents at International Meeting for Autism Research
14-May-2014
Appendix 3B
30-Apr-2014
Appendix 3B
30-Apr-2014
AGM Results of Meeting
30-Apr-2014
Chairman's AGM Address to Shareholders
30-Apr-2014
Appendix 4C - quarterly
2-Apr-2014
Presentation at Morgans Emerging Companies Conference
27-Mar-2014
Notice of Annual General Meeting - Proxy Form
27-Mar-2014
Appendix 3B
27-Mar-2014
2013 Annual Report
7-Mar-2014
ZSP S and P DJ Indices Announces March Quarterly Rebalance
27-Feb-2014
Neuren reports financial results for 2013
27-Feb-2014
Preliminary Final Report and audited Financial Statements
21-Feb-2014
Appendix 3B
14-Feb-2014
Appendix 3B
28-Jan-2014
Neuren reports progress in NNZ-2566 clinical trial programs
15-Jan-2014
Appendix 3B
2-Jan-2014
Appendix 3B
29-Nov-2013
Appendix 3B
27-Nov-2013
Appendix 3B
27-Nov-2013
Neuren Share Purchase Plan raises $2 million
20-Nov-2013
Ceasing to be a substantial holder
19-Nov-2013
Investor presentation, 19 November 2013
15-Nov-2013
Appendix 3B
14-Nov-2013
Change in substantial holding
12-Nov-2013
Appendix 3B
6-Nov-2013
Change of Director's Interest Notice
4-Nov-2013
Share Purchase Plan record date
4-Nov-2013
SPP Certification
4-Nov-2013
Appendix 3B
31-Oct-2013
Becoming a substantial holder
30-Oct-2013
Share Purchase Plan offer documents
30-Oct-2013
Orphan drug designation from FDA for NNZ-2566 in Fragile X
28-Oct-2013
Section 708A(5)e Notice
28-Oct-2013
Appendix 3B
22-Oct-2013
Placement of $21.5m to accelerate execution of strategy
18-Oct-2013
Neuren receives Fast Track designation for Fragile X
18-Oct-2013
Trading Halt
10-Oct-2013
Appendix 3B
9-Oct-2013
Response to ASX Price Query
9-Oct-2013
Investor presentation
1-Oct-2013
Neuren data presented at Fragile X Foundation meeting
26-Sep-2013
Appendix 3B
19-Sep-2013
Change of Director's Interest Notice
11-Sep-2013
Appendix 3B
9-Sep-2013
Neuren opens new IND for NNZ-2566 in Fragile X Syndrome
4-Sep-2013
Final Director's Interest Notice
2-Sep-2013
Neuren announces changes to its leadership team
29-Aug-2013
Half Yearly Report and Accounts
5-Aug-2013
Notice under section 708A(5)(e) of the Corporations Act
5-Aug-2013
Response to social media commentary re Rett trial
5-Aug-2013
Trading Halt Request
5-Aug-2013
Trading Halt
30-Jul-2013
Investor presentation July 2013
30-Jul-2013
Appendix 3B Option Exercise
29-Jul-2013
Results in Fragile X Model with NNZ 2591
26-Jul-2013
Response to ASX Price Query
12-Jul-2013
Neuren receives two new patents
11-Jul-2013
Notice under section 708A(5)(e) of the Corporations Act
11-Jul-2013
Appendix 3B Option Exercise amended
11-Jul-2013
Appendix 3B Option Exercise
26-Jun-2013
Notice under section 708A(5)(e) of the Corporations Act
26-Jun-2013
Appendix 3B Option Exercise
25-Jun-2013
Response to ASX Price Query Letter
18-Jun-2013
Notice under section 708A(5)(e) of the Corporations Act
12-Jun-2013
Appendix 3B Option Exercise
5-Jun-2013
FDA Fast Track granted for NNZ2566 Rett program
29-May-2013
Change of Director's Interest Notice
29-May-2013
Appendix 3B Equity Performance Rights
29-May-2013
Appendix 3B Loan Funded Shares
29-May-2013
Notice under section 708A(5)(e) of the Corporations Act
24-May-2013
CFO appointment
22-May-2013
Final Director's Interest Notice
22-May-2013
Final Director's Interest Notice
22-May-2013
Appendix 3B Exercise of Options
22-May-2013
Lapse of Unlisted Options
22-May-2013
Change of Director's Interest Notice
22-May-2013
Change of Director's Interest Notice
21-May-2013
Investor Presentation May 2013
20-May-2013
Results of Meeting
20-May-2013
CEO Presentation to AGM
20-May-2013
Chairman's Address to AGM
15-May-2013
Response to ASX Price Query Letter
19-Apr-2013
Notice of Annual General Meeting/Proxy Form
15-Apr-2013
Shareholder Update
4-Apr-2013
Ceasing to be a substantial holder
28-Mar-2013
Annual Report to shareholders
28-Feb-2013
Preliminary Final Report
1-Feb-2013
Initial Director's Interest Notice
31-Jan-2013
Dr Richard Treagus joins Neuren Board
9-Jan-2013
Neuren appoints Nancy Jones SD Clinical & Medical Affairs
24-Dec-2012
Neuren IND open for Rett Phase II trial
20-Dec-2012
Appendix 3B
30-Nov-2012
Neuren TAP Conference presentation and Fragile X results
22-Nov-2012
Neuren completes Phase I NNZ2566 study/files Phase II IND
9-Nov-2012
Amended 2 - Change in substantial holding
9-Nov-2012
Amended Change in substantial holding
9-Nov-2012
Change in substantial holding
25-Oct-2012
Response to ASX Price Query
19-Oct-2012
NNZ2566 selected as Windhover Top 10 Neuroscience Project
30-Aug-2012
Half Yearly Report and Accounts
9-Aug-2012
Neuren appoints Joe Horrigan VP Clinical and Medical Affairs
7-Aug-2012
NNZ2566 Rationale in ASDs
6-Jul-2012
Neuren awarded Rett Syndrome trial grant
8-Jun-2012
Final Director`s Interest Notice
8-Jun-2012
Initial Director`s Interest Notice
31-May-2012
Results of Meeting
31-May-2012
CEO`s address to AGM
29-May-2012
Neuren announces cancer xenograft testing results
25-May-2012
Change in substantial holding
16-May-2012
Rett Syndrome pre-IND meeting held with FDA
2-May-2012
Notice under section 708A(5)(e) of the Corporations Act
27-Apr-2012
Appendix 3B (exercise of options)
27-Apr-2012
Notice of Annual General Meeting/Proxy Form
19-Apr-2012
Response to ASX Price Query
30-Mar-2012
Neuren 2011 Annual Report
8-Mar-2012
Initial Director`s Interest Notice
8-Mar-2012
Neuren appoints Bruce Hancox to board of directors
8-Mar-2012
Neuren presentation to Arrowhead TBI Conference
29-Feb-2012
Neuren 2011 Preliminary Final Report
22-Dec-2011
Neuren to proceed with oral NNZ2566 trial
12-Dec-2011
Change in substantial holding
9-Dec-2011
Response to ASX Price Query
21-Nov-2011
Neuren Completes Phase II trial Cohort 2
7-Nov-2011
Appendix 3B (exercise of options)
3-Nov-2011
Change in substantial holding
3-Nov-2011
Change in substantial holding
26-Oct-2011
Appendix 3B (amendment)
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Appendix 3B
20-Oct-2011
Response to ASX Price Query
30-Aug-2011
Half Yearly Report and Accounts
17-Aug-2011
Becoming a substantial holder
16-Aug-2011
Becoming a substantial holder
16-Aug-2011
Notice under section 708A(5)(e) of the Corporations Act
16-Aug-2011
Appendix 3B
16-Aug-2011
Neuren places $3m of rights issue shortfall
29-Jul-2011
Appendix 4C - quarterly
27-Jul-2011
NEU Broker Presentation July 2011
22-Jul-2011
Neuren CEO presentation to Bioshares Biotech Summit
21-Jul-2011
Change of Director`s Interest Notice
21-Jul-2011
Change of Director`s Interest Notice
19-Jul-2011
Appendix 3B
19-Jul-2011
Results of Neuren Rights Issue
29-Jun-2011
Neuren Confirms Despatch of Rights Issue Offer Documents
28-Jun-2011
Appendix 3B
24-Jun-2011
CEO presentation to AusBiotech New York
20-Jun-2011
Rights Issue Eligible Shareholder Notice
20-Jun-2011
Change in substantial holding
15-Jun-2011
Rights Issue Notice to Foreign Shareholders
15-Jun-2011
Rights Issue Notice to Optionholders
15-Jun-2011
Rights Issue Notice under Section 708AA
15-Jun-2011
Appendix 3B (renounceable rights issue)
15-Jun-2011
Neuren Rights Issue Letter of Offer (Australian residents)
15-Jun-2011
Neuren Rights Issue Offer Document (NZ residents)
15-Jun-2011
Neuren announces Renounceable Rights Issue
6-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
6-Jun-2011
Neuren completes placement and converts remaining note
6-Jun-2011
Appendix 3B (options)
6-Jun-2011
Appendix 3B (shares)
3-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
3-Jun-2011
Appendix 3B
2-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
2-Jun-2011
Appendix 3B
31-May-2011
Results of Annual Meeting
31-May-2011
Results of Special Meeting
31-May-2011
Neuren CEO Presentation to AGM
20-May-2011
Neuren reduces outstanding convertible note principal
19-May-2011
Neuren`s Perseis selects lead antibodies
13-May-2011
Notice of Special Shareholders Meeting/Proxy Form
11-May-2011
Neuren Completes Phase II trial Cohort 1
6-May-2011
Notice under section 708A(5)(e) of the Corporations Act
6-May-2011
Appendix 3B
5-May-2011
Becoming a substantial holder
4-May-2011
Neuren Announces Private Placement and Rights Issue
2-May-2011
Trading Halt
29-Apr-2011
Notice of Annual General Meeting/Proxy Form
27-Apr-2011
Appendix 3B
20-Apr-2011
Notice under section 708A(5)(e) of the Corporations Act
20-Apr-2011
Appendix 3B
20-Apr-2011
Appendix 3B
31-Mar-2011
Annual Report to shareholders
23-Mar-2011
Appendix 3B
22-Mar-2011
Notice under section 708A(5)(e) of the Corporations Act
21-Mar-2011
Appendix 3B
21-Mar-2011
Appendix 3B
21-Mar-2011
Appendix 3B
21-Mar-2011
Results of Meeting
10-Mar-2011
Response to ASX Price Query
3-Mar-2011
Notice of Special Shareholders Meeting
28-Feb-2011
Preliminary Final Report
21-Feb-2011
Appendix 3B
18-Feb-2011
Notice under section 708A(5)(e) of the Corporations Act
18-Feb-2011
Appendix 3B
8-Feb-2011
Lapse of unquoted options
21-Jan-2011
Appendix 3B
21-Jan-2011
Appendix 3B (amended)
19-Jan-2011
Notice under section 708A(5)(e) of the Corporations Act
19-Jan-2011
Appendix 3B
19-Jan-2011
Appendix 3B
22-Dec-2010
Appendix 3B
20-Dec-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Dec-2010
Securities Trading Policy
20-Dec-2010
Appendix 3B
20-Dec-2010
Appendix 3B
22-Nov-2010
Appendix 3B
19-Nov-2010
Notice under section 708A(5)(e) of the Corporations Act
19-Nov-2010
Appendix 3B
19-Nov-2010
Appendix 3B
18-Nov-2010
Neuren Initiates NNZ2566 Oral Formulation Development
16-Nov-2010
Neuren Completes Additional Phase I Study for TBI
27-Oct-2010
Appendix 3B
20-Oct-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Oct-2010
Appendix 3B
20-Oct-2010
Appendix 3B
7-Oct-2010
Lapse of unquoted options
23-Sep-2010
Appendix 3B
21-Sep-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Sep-2010
Appendix 3B
21-Sep-2010
Appendix 3B
26-Aug-2010
Half Yearly Report and Accounts
25-Aug-2010
Appendix 3B
20-Aug-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Aug-2010
Appendix 3B
20-Aug-2010
Appendix 3B
23-Jul-2010
Appendix 3B
21-Jul-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Jul-2010
SpringTree becomes a substantial shareholder
21-Jul-2010
Appendix 3B
21-Jul-2010
Appendix 3B
24-Jun-2010
Appendix 3B
21-Jun-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Jun-2010
Appendix 3B (options)
21-Jun-2010
Appendix 3B (shares)
27-May-2010
Appendix 3B
25-May-2010
Results of Meeting
25-May-2010
CEO Presentation to AGM
21-May-2010
Notice under section 708A(5)(e) of the Corporations Act
21-May-2010
Appendix 3B
21-May-2010
Appendix 3B
6-May-2010
Neuren Starts Phase II Trial of NNZ2566
27-Apr-2010
Notice of Annual General Meeting/Proxy Form
23-Apr-2010
Appendix 3B (convertible note)
21-Apr-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Apr-2010
Appendix 3B (options)
21-Apr-2010
Appendix 3B (shares)
6-Apr-2010
Lapse of unquoted options
30-Mar-2010
Annual Report to shareholders
25-Mar-2010
Appendix 3B - ESOP
24-Mar-2010
Appendix 3B (convertible note)
22-Mar-2010
Notice under section 708A(5)(e) of the Corporations Act
22-Mar-2010
Appendix 3B
22-Mar-2010
Appendix 3B
19-Mar-2010
Grant funding for TFF oncology program
3-Mar-2010
Trial of Second Neuren Drug Motiva to be Initiated
26-Feb-2010
Preliminary Final Report
22-Feb-2010
Appendix 3B (convertible note)
18-Feb-2010
Notice under section 708A(5)(e) of the Corporations Act
18-Feb-2010
Appendix 3B (options)
18-Feb-2010
Appendix 3B (shares)
12-Feb-2010
Ceasing to be a substantial holder
12-Feb-2010
Change in substantial holding
12-Feb-2010
Change in substantial holding
12-Feb-2010
Change in substantial holding
11-Feb-2010
Cato strategic partnership and appoints US CMO
20-Jan-2010
Appendix 3B
13-Jan-2010
Change in substantial holding
24-Dec-2009
Change of Director`s Interest Notice
23-Dec-2009
Notice under section 708A(5)(e) of the Corporations Act
23-Dec-2009
Appendix 3B (options)
23-Dec-2009
Appendix 3B (shares)
23-Dec-2009
Neuren Completes Shareholder Approved Funding
22-Dec-2009
Results of Special Shareholders Meeting
15-Dec-2009
Initial Director`s Interest Notice
4-Dec-2009
Notice under section 708A(5)(e) of the Corporations Act
4-Dec-2009
Appendix 3B
4-Dec-2009
Notice of Special Shareholders Meeting
25-Nov-2009
Dr John Holaday joins Neuren Board
18-Nov-2009
Appendix 3B (options)
18-Nov-2009
Notice under section 708A(5)(e) of the Corporations Act
18-Nov-2009
Appendix 3B (notes)
18-Nov-2009
Appendix 3B (shares)
18-Nov-2009
Neuren Arranges up to AU$7.8m in New Funding
18-Nov-2009
Reinstatement to Official Quotation
16-Nov-2009
Suspension from Official Quotation
12-Nov-2009
Trading Halt
25-Sep-2009
Notice under section 708A(5)(e) of the Corporations Act
25-Sep-2009
Appendix 3B
22-Sep-2009
Reponse to Price Query
31-Aug-2009
Half Year Report and Accounts
14-Aug-2009
Appendix 3B
14-Aug-2009
Neuren raises NZ$1 million through SPP
22-Jul-2009
Neuren SPP section 708A notice
21-Jul-2009
SPP NZ Certification
20-Jul-2009
Neuren NNZ-2566 Development Overview
20-Jul-2009
Neuren Share Purchase Plan
20-Jul-2009
Neuren Chairmans SPP Letter
15-Jul-2009
SPP terms update
10-Jul-2009
Neuren Share Purchase Plan
2-Jul-2009
Ceasing to be a substantial holder
1-Jul-2009
Neuren obtains further US$14m US Army funding
28-May-2009
Results of Meeting
28-May-2009
Presentation to AGM
28-May-2009
Chairman`s Address to Shareholders
28-Apr-2009
Notice of Annual General Meeting/Proxy Form
22-Apr-2009
Neuren Progresses Cancer Program
21-Apr-2009
Trading Halt
17-Apr-2009
Response to ASX Price Query
16-Apr-2009
Trading Halt
1-Apr-2009
Lapse of unquoted options
31-Mar-2009
Annual Report to shareholders
30-Mar-2009
Final Director`s Interest Notice
27-Feb-2009
Preliminary Final Report
21-Jan-2009
Neuren Strategy Update
20-Jan-2009
Respone to ASX price query
19-Jan-2009
Trading Halt
14-Jan-2009
Change of Director`s Interest Notice
24-Dec-2008
Neuren Announces Glypromate Trial Preliminary Results
10-Nov-2008
Phase 3 trial data collection completed
30-Sep-2008
Appendix 3B
30-Sep-2008
Change of Director`s Interest Notice
30-Sep-2008
Change of Director`s Interest Notice
30-Sep-2008
Neuren raises $2m through underwritten SPP
30-Sep-2008
Appendix 3B
4-Sep-2008
US Army to provide additional NNZ2566 trial funding
29-Aug-2008
Half Yearly Report and Accounts
28-Aug-2008
Results of Special Shareholders` Meeting
27-Aug-2008
Neuren extends SPP closing date
27-Aug-2008
Neuren signs cancer license and collaboration agreement
21-Aug-2008
NZ Securities Act certification for SPP
15-Aug-2008
Share Purchase Plan letter to eligible shareholders
15-Aug-2008
Notice under section 708A(5)(e) of the Corporations Act
12-Aug-2008
Change in substantial holding
12-Aug-2008
Notice of Special Meeting
6-Aug-2008
Neuren Share Purchase Plan
6-Aug-2008
Appendix 3B
6-Aug-2008
Neuren raises a minimum of $3 million
6-Aug-2008
Reinstatement to Official Quotation
4-Aug-2008
Voluntary Suspension extended
31-Jul-2008
Suspension from Official Quotation
29-Jul-2008
Trading Halt
21-Jul-2008
Glypromate and NNZ 2566 in Top 10 Neuroscience Projects
16-Jul-2008
NEU Completes Glypromate Phase 3 Recruitment